Abstract
Osteosarcoma ranks first in both morbidity and mortality among primary bone tumors. This study aimed to investigate the effect of up-regulation of PRR11 on the malignancy of osteosarcoma and its clinical significance. The expression, biological function, related pathways of PRR11 in osteosarcoma and its impact on prognosis were explored through the bioinformatics database. After PRR11 was up-regulated, cell proliferation, invasion, migration and apoptosis were detected by the cell counting kit-8 method, Transwell, scratch, and flow cytometry. PRR11 is highly expressed in a variety of malignant tumors, including osteosarcoma tissue and cells, and has a significant impact on prognosis. Univariate Cox regression analysis revealed that PRR11 was an independent prognostic factor for osteosarcoma. The gene set enrichment analysis results showed that the differential genes were mainly enriched in the biological process of the cell cycle; the protein-protein interaction network mainly interacted with the regulatory genes of the cell cycle. PRR11 promotes the invasion, migration, and proliferation of osteosarcoma cells and inhibits their apoptosis. Comprehensive bioinformatics analysis revealed that PRR11 promotes the malignancy of osteosarcoma cells mainly by participating in cell cycle regulation, and has an important impact on osteosarcoma prognosis. PRR11 may provide the basis for prognosis and treatment in patients with osteosarcoma.
Introduction
Osteosarcoma (OS) is the most common and deadly primary bone malignancy, particularly affecting children and young adults. While surgical and chemotherapeutic advancements have pushed the five-year survival rate for localized cases to 60–70%, patients with recurrent or metastatic disease face a grim 20% survival rate. The field has hit a therapeutic bottleneck, necessitating the identification of molecular drivers of tumor malignancy. This study investigates PRR11 (Proline-Rich Protein 11), a gene located on chromosome 17q22, which has been implicated in various cancers but whose specific impact on osteosarcoma progression remained largely unexplored.
Methods and Datasets
The researchers employed a dual-track approach, combining large-scale bioinformatics data mining with in vitro experimental validation.
- Bioinformatics Analysis: Databases such as GEPIA and CCLE were used to compare PRR11 expression across tissues and cell lines. Transcriptome and clinical data for 265 osteosarcoma patients were sourced from The Cancer Genome Atlas (TCGA).
- Functional Assays: The MG-63 osteosarcoma cell line was transfected to overexpress PRR11. Functional consequences were measured using CCK-8 assays (proliferation), Transwell and scratch tests (invasion/migration), and flow cytometry (apoptosis).
- Pathway Analysis: Gene Set Enrichment Analysis (GSEA) and Protein-Protein Interaction (PPI) networks (via STRING) were used to identify PRR11-related biological processes.
Results
PRR11 Expression and Clinical Significance
Bioinformatics analysis revealed that PRR11 is significantly up-regulated in a wide array of malignant tumors. In the Cancer Cell Line Encyclopedia (CCLE) ranking, osteosarcoma was among the top cell lines for PRR11 expression, indicating its potential as a critical oncogenic driver in this specific tissue type.
Univariate Cox regression analysis identified PRR11 as an independent prognostic factor. High PRR11 expression correlates with known risk factors such as tumor metastasis and recurrence, even when accounting for other clinical variables.
Impact on Patient Survival
Kaplan-Meier survival analysis demonstrated a stark contrast in outcomes based on PRR11 levels. Patients with low PRR11 expression exhibited significantly better overall survival (OS) and disease-specific survival (DSS) compared to those with high expression (p < 0.05).
Biological Mechanisms of Malignancy
Experimental validation in MG-63 cells confirmed that PRR11 overexpression promotes a "triple threat" of oncogenic behaviors: increased proliferation, enhanced migration/invasion, and inhibited apoptosis. GSEA and PPI analysis converged on cell cycle regulation as the primary mechanism. PRR11 interacts with hub proteins like CDC20 and CCNA2, which are critical for nuclear division and cellular stability.
Discussion and Conclusion
PRR11 serves as a critical oncogenic driver in osteosarcoma by accelerating the cell cycle and suppressing programmed cell death. Its role as an independent prognostic biomarker suggests it could be used to stratify patient risk and guide treatment intensity.
While this study provides robust evidence for PRR11's clinical significance, further research is needed to elucidate the exact biochemical signaling cascades involved. Future work should also include in vivo animal models to evaluate the therapeutic potential of PRR11 inhibition. Ultimately, PRR11 represents a promising target for the development of gene-targeted therapies in osteosarcoma.
Summary updated